←
Lightstone Ventures47 posts
Lightstone Ventures avatar

Lightstone Ventures

@LightstoneVC

Dedicated to empowering entrepreneurs with the resources and guidance needed to bring their innovative therapeutics to patients.

◷ Joined August 2021▧ 9 Photos and videos
Lightstone Ventures avatar
Lightstone Ventures@LightstoneVC·22 Apr 2025

Congrats to @Tagworkspharma on this significant milestone! Great news for patients as the Company enters clinical development of their Phase 1 trial of TGW101, a first-in-class antibody drug-conjugate targeting tumor associated glycoprotein 72 (TAG-72) in advanced #solidtumors.

We’re thrilled to announce the initiation of our Phase 1 clinical trial evaluating TGW101, an #ADC developed with our Click-to-Release treatment platform, in patients with advanced #solidtumors. Learn more: bit.ly/4jrAErw

Post attachment
Lightstone Ventures avatar
Lightstone Ventures@LightstoneVC·21 Jan 2025

Please join us in welcoming H. Martin Seidel, Ph.D., to the Lightstone team as Advisor. Dr. Seidel brings over 30 years of experience across R&D and Business Development in both pharma and biotech to our team. We look forward to working with you!

Post attachment
Lightstone Ventures avatar
Lightstone Ventures@LightstoneVC·17 Dec 2024

Congratulations to Brendan Kelly, PhD, on his promotion to Principal at Lightstone Ventures! As a core member of our investment team, we celebrate Brendan’s leadership and contributions across our portfolio. We look forward to continuing our exciting work together!

Post attachment
Lightstone Ventures avatar
Lightstone Ventures@LightstoneVC·1 Oct 2024

We welcome Ken Mills as CEO and member of the Board of Directors for @tagworkspharma as the company expects to embark on its next phase of growth and enter the clinic in 2025 with its lead antibody-drug conjugate program, TGW101.

We're excited to announce Ken Mills has been appointed our new CEO and that Marc Robillard will continue as CSO & Board member. We look forward to working to bring our Click-to-Release platform and lead ADC program for solid tumors into the clinic in 2025. prnewswire.com/news-releases…

Post attachment
Lightstone Ventures avatar
Lightstone Ventures@LightstoneVC·21 May 2024

Lightstone portfolio company @VoltaMedical announced positive results from their TAILORED-AF trial, comparing AI-assisted ablation procedure with the conventional treatment for persistent atrial fibrillation patients. Learn more about what was presented: bit.ly/3yEkKXW

Lightstone Ventures avatar
Lightstone Ventures@LightstoneVC·26 Apr 2024

Congrats to @cerevance, who announced the closing of their Series B-1 Extension financing round. Lightstone is a proud fund partner, and we look forward to company updates as they progress their pipeline of therapies for CNS diseases. Read more: bit.ly/44jBxeS

We’re pleased to announce the addition of $47M to our Series B-1 Extension to advance our CVN424 therapy for the treatment of PD into a Phase 3 clinical trial and to support our robust pipeline of CNS treatments. Read more here: brnw.ch/21wJaqe

Lightstone Ventures avatar
Lightstone Ventures@LightstoneVC·16 Apr 2024

Welcome José-Alain Sahel, M.D., to Lightstone, joining us as an advisor. A distinguished professor and leader in the Ophthalmology and Neuroscience space, Dr. Sahel’s deep knowledge will play a key role in supporting new and existing portfolio companies.

Post attachment
Lightstone Ventures avatar
Lightstone Ventures@LightstoneVC·19 Dec 2023

Congratulations to Jingjing Wang, Ph.D. on her promotion to Vice President at Lightstone! As a core member of our investment team, we look forward to exciting things to come as we continue our work together.

Post attachment
Lightstone Ventures avatar
Lightstone Ventures@LightstoneVC·21 Nov 2023

Congratulations to @RelievantMed, that has developed and commercialized the Intracept® Procedure, their FDA-cleared treatment for chronic #vertebrogenic pain, on being acquired by @bostonsci! Great news and great for patients. Learn more here: bit.ly/3sNpJTH

Relievant is now Boston Scientific. Follow @bostonsci to stay up to date as we advance pain management solutions as part of Neuromodulation at Boston Scientific. Learn more here: bit.ly/3sNpJTH

Post attachment
Lightstone Ventures avatar
Lightstone Ventures@LightstoneVC·5 Oct 2023

Today, the launch of 65LAB was announced, a company creation vehicle designed to advance drug discovery & new therapeutics companies in Singapore. As a proud founding partner, we look forward to the potential patient impact of these discoveries. Read more: prn.to/3LJD0TO

Post attachment
Lightstone Ventures avatar
Lightstone Ventures@LightstoneVC·21 Sep 2023

Sharing an exciting update from @cerevance, who recently announced that the first patient has been dosed in their Phase 1 study evaluating safety and tolerability of CVN293, for the treatment of #ALS and #Alzheimers. Full press release: bit.ly/3Lyr4nL

We’re pleased to announce that the first subject has been dosed in our Phase 1 clinical study evaluating CVN293, a selective inhibitor designed to modulate neuroinflammation for the treatment of ALS and Alzheimer’s disease. Read the release to learn more: brnw.ch/21wCJ2h

Lightstone Ventures avatar
Lightstone Ventures@LightstoneVC·7 Sep 2023

Congratulations to @NimbusTx, on the closing of their $210 million private financing! Lightstone is a proud fund partner, and we look forward to updates as the company advances their pipeline in immunology, cancer and metabolic disease. Learn more: bit.ly/3LfQSF4

We’re excited to announce a $210 million private financing to advance our next wave of tech-enabled small molecule medicines. Learn more: bit.ly/47VJ0Ca

0:20
Lightstone Ventures avatar
Lightstone Ventures@LightstoneVC·30 Aug 2023

Congrats to @Cerevance for being named one of @FierceBiotech’s 2023 #Fierce15 biotech companies. We’re looking forward to seeing more great accomplishments from Cerevance in the future!

We’re thrilled to announce that @FierceBiotech has named us a #Fierce15 biotech company of 2023. It is an honor to be acknowledged within this outstanding array of industry experts, and a testament to the groundbreaking work we are doing at Cerevance: brnw.ch/21wC3bg

Post attachment